Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
On Thursday, September 24, the RARE Foundation and Expecting Health co-hosted the 8th Annual Newborn Screening Bootcamp!
Original title: “RECAP: 8th Annual Newborn Screening Bootcamp ”
The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind its counterparts in the U.S. and China.
Original title: “Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds”
More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.
Original title: “ArriVent collapses on disappointing lung cancer data”
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.
Original title: “Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial”
Despite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.
Original title: “FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues”
AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large B cell lymphoma—potentially setting up a battle with Roche's Polivy.
Original title: “AbbVie, Genmab's Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3”
While AI is taking off in biopharma for administrative tasks and drug discovery efforts, more than 90% of drugmakers have yet to commit to scaling AI use in regulated biopharma manufacturing, according to CRB’s new Horizons: Life Sciences report.
Original title: “Compliance concerns hinder rollout of AI in drug manufacturing: Survey”
intrahepatic tissue resident cd8 t cell programmes associate with fibrosis and local immune remodelling in autoimmune hepatitis
Original title: “Intrahepatic Tissue-Resident CD8(+) T-Cell Programmes Associate With Fibrosis and Local Immune Remodelling in Autoimmune Hepatitis.”
photobiomodulation ameliorates alexander disease through ampk mtor mediated mitophagy
Original title: “Photobiomodulation Ameliorates Alexander Disease Through AMPK/mTOR-Mediated Mitophagy.”
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.
Original title: “The top biopharma conferences in 2027”
The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive drugs used in PET imaging.
Original title: “GE HealthCare to acquire Sofie Biosciences for $945M”